UNSPSC 51362505: Iminophenimide

This classification denotes a sedative and hypnotic with the molecular formula C12H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H0X939RX9W, chemically known as 3-ethyl-3-phenyl-2,6-piperazindion but generally known as iminophenimide, which bears US NIH Compound Identifier 163317. European Medicines Agency schedules Iminophenimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08150MIG.

UNSPSC 51362505 Iminophenimide is a Commodity code that in recent state and local procurement activity appears to tag pharmaceutical and health-related product sourcing rather than narrow to iminophenimide compounds alone. State and local health agencies and cooperative purchasing organizations are using this code to procure naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative frameworks. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as recent active buyers. Procurements under the code combine direct county purchases with statewide cooperative agreements designed to aggregate demand across participating municipalities and state facilities.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023; vendors must submit bids through the county's e-Procurement Portal and include all shipping and delivery costs. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with a response deadline of March 26, 2026; awarded vendors supply through three authorized wholesalers and must demonstrate cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future procurement intent around direct contracting models outside traditional pharmacy benefit manager arrangements.